quantisnow
FeedTopReportsPricing
⌘K
Live feed
17:40:03·90d
INSIDERFiling
Oruka Therapeutics Inc. logo

SVP, Finance Agarwal Arjun was granted 17,500 shares, increasing direct ownership by 995% to 19,258 units (SEC Form 4)

ORKA· Oruka Therapeutics Inc.
Health Care
Original source

Companies

  • ORKA
    Oruka Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Dec 18UpdatePiper Sandler$75.00
  • Nov 13UpdateJefferies$45.00
  • Oct 27UpdateGuggenheim$60.00
  • Oct 13UpdateBarclays$48.00
  • May 22UpdateBTIG Research$44.00
  • Feb 4UpdateWolfe Research$20.00

Related

  • SEC2d
    SEC Form 424B7 filed by Oruka Therapeutics Inc.
  • SEC6d
    SEC Form DEFA14A filed by Oruka Therapeutics Inc.
  • SEC6d
    SEC Form DEF 14A filed by Oruka Therapeutics Inc.
  • INSIDER8d
    SEC Form 4 filed by Goncalves Joana
  • SEC11d
    SEC Form EFFECT filed by Oruka Therapeutics Inc.
  • SEC21d
    SEC Form S-3 filed by Oruka Therapeutics Inc.
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.
  • INSIDER37d
    Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022